![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Middle Cerebral Artery Pulsatility Is Highly Associated with Systemic Blood Viscosity in Acute Ischemic Stroke within 24 Hours of Symptom Onset |
Ji Eun Han, Taemin Kim, Joong Hyun Park, Jong Sam Baik, Jeong Yeon Kim, Jae Hyeon Park, Sang Won Han, Hyun-Jeung Yu |
J Neurosonol Neuroimag. 2019;11(2):126-131. Published online November 22, 2019 DOI: https://doi.org/10.31728/jnn.2019.00050 |
Middle Cerebral Artery Pulsatility Is Highly Associated with Systemic Blood Viscosity in Acute Ischemic Stroke within 24 Hours of Symptom Onset Prior antithrombotic use is significantly associated with decreased blood viscosity within 24 hours of symptom onset in patients with acute ischemic stroke The rCBV Ratio Is a Predictive Factor for Developing Malignant Middle Cerebral Artery Infarction within 6 Hours of Symptom Onset Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset Is there association between hyperdense middle cerebral artery sign on CT scan and time from stroke onset within the first 24-hours? Outcomes of Emergent Carotid Artery Stenting within 6 Hours of Symptom Onset in Patients with Acute Ischemic Stroke Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials Endovascular Therapy for Middle Cerebral Artery Occlusions Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom Onset OPL065 Combined safety analysis of desmoteplase in acute ischemic stroke 3 to 9 hours after stroke symptom onset from two independent phase II studies (DIAS and DEDAS) |